SUMERGlimepiride vs Sitagliptin for HbA1c Reduction in Type 2 Diabetes

Study start date: July 1, 2009

Inclusion criteria: * Subject naïve to treatment * HbA1c \> 8.5 up to 11 % * Lipid lowering therapy, antihypertensive, hormonal substitutes, thyroid hormone substitutes, and contraceptives are allowed as long as they are kept at a stable dosing Exclusion criteria: * Treatment with any oral antidiabetics or insulin * Known type 1 Diabetes Mellitus * Pregnant or breast feeding women * Ketoacidosis history * History of sensitivity to any of the active substances * Renal dysfunction : serum creatinine \> or = 1.5 mg/dL in male subjects \> or = 1.4 mg/dL in female subjects * Liver impairment (ALT, AST \> 3-fold the upper limit of normal range) * Systemic corticosteroid treatment 3 months prior to study or during the study * Drug or alcohol abuse history * Patients with history of acute coronary syndrome, cerebrovascular events/transient ischaemic attack in the last three months * Presence of any condition (medical, psychological, social or geographic) current or previously seen that according to Investigators judgment jeopardizes the safety or restricts the participation of the patient during the study * Neoplasias The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.